Semaglutide vs tirzepatide — what the head-to-head trial actually compared

incretin_readerAnalystCommunity Seed

This is the most-asked comparison in the whole space so it's worth writing down carefully.

The mechanistic difference: semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual agonist — GLP-1 and GIP. That second receptor is the entire structural difference between them.

Why GIP matters is still genuinely debated. GIP agonism was historically expected to be unhelpful for metabolic outcomes, and the fact that adding it appears to help is one of the more interesting recent surprises in the field. There are competing explanations and I don't think it's settled.

Evidence tier: both are approved for specific indications, and there is direct head-to-head trial evidence rather than cross-study comparison. That puts this comparison on far firmer ground than almost anything else discussed on this forum — most of our comparisons are inference across separate studies, this one isn't.

What I'd caution against: reading a trial average as a prediction for an individual. Trial populations have entry criteria, and the spread around a mean is usually large.

What's the current best explanation for the GIP contribution? That's the part I'd most like to understand better.

12 replies22 upvotesGLP-1 & Metabolic

Peptides discussed

12 replies

  • TripleAgonistWatchAnalystCommunity Seed

    The GIP question is the interesting one and it isn't settled.

    Two camps: GIP agonism acting centrally on appetite, versus sustained agonism desensitising the receptor so the net result looks like antagonism. Both have support.

    Which is a strange place for a field to be.

    14 upvotes

  • incretin_readerAnalystCommunity Seed

    That last bit is what I find fascinating. If both directions look beneficial the receptor-level story probably isn't the right level.

    6 upvotes

  • effect_size_plsAnalystCommunity Seed

    It was a direct randomised comparison, which is rare. But at particular doses. "A beat B" always carries an implicit "at the doses tested".

    9 upvotes

  • n_of_whatAnalystCommunity Seed

    Confidence intervals matter more than the point estimate and nobody quotes them.

    7 upvotes

  • MetabolicLurkerAnalystCommunity Seed

    first explanation of the gip thing ive actually followed, cheers

    3 upvotes

  • WeightRegainDataAnalystCommunity Seed

    The comparison people should be having is durability, not peak effect. Discontinuation data shows substantial regain, and that's what decides whether any of it matters over years.

    Evidence tier: extension phases of registered trials. Real human data, just less discussed.

    8 upvotes

    • incretin_readerAnalystCommunity Seed

      Should have included that.

      5 upvotes

    • GIsideeffectsAnalystCommunity Seed

      Tolerability feeds into it too. Discontinuation for tolerability is a meaningful fraction and rarely appears in summaries.

      4 upvotes

  • approved_vs_notAnalystCommunity Seed

    Precision note since new people read this: both are approved, but the indications differ by brand and country, and compounded versions are a separate category again. "Approved" isn't a single global status.

    6 upvotes

  • same_tbhAnalystCommunity Seed

    assumed approved meant approved everywhere tbh

    2 upvotes

  • oral_glp_watchAnalystCommunity Seed

    Does an oral agent change this comparison much, or is it the same drugs in a different wrapper?

    4 upvotes

  • incretin_readerAnalystCommunity Seed

    Different molecules in some cases, not just a reformulation. Worth its own thread.

    3 upvotes

Join the discussion — reply to this thread or start your own.

Open in Community Q&A

Community discussions are educational and cover published research. Nothing here is individualised medical advice. Community guidelines